ClinicalTrials.gg
RecruitingNCT06736665ORBIT-SHOCKUpdated Apr 30, 2026

Orbital Atherectomy vs Intravascular Lithotripsy for the Treatment of Calcified Coronary Nodules (ORBIT-SHOCK).

An interventional study of Orbital atherectomy and Intravascular lithotripsy in Coronary Arterial Disease (CAD), Coronary Calcification and Coronary Calcified Nodules, sponsored by Spanish Society of Cardiology. Recruiting at 6 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by Spanish Society of Cardiology · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 85 studies in Acute Coronary Syndrome with a site in Spain — 13 open to participants now, 16 under way, 1 of them phase 3. Acute Coronary Syndrome · Spain.

Planned enrollment
56th of 60
50 · median 588
Started
2025
with 5 others
No phase
24 of 85
4 open now
Primary completion
2026-12
later than 6 of 15 live
Registered
74th of 85
by date

Among the 85 studies in Acute Coronary Syndrome with a site in Spain, this one is the 56th largest by planned enrollment of the 60 interventional ones that give a count, is one of 6 that started in 2025, is one of 24 with no phase, reaches primary completion later than 6 of the 15 other live ones, and was the 74th registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

13 of the 85 studies in Acute Coronary Syndrome with a site in Spain are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Acute Coronary Syndrome with a site in Spain, or all of them as a file.
02

Study summary

The ORBIT-SHOCK pilot study is a multicenter, prospective, randomized clinical trial initiated by investigators. It will include patients diagnosed with atherosclerotic coronary artery disease presenting calcified nodules (CN), identified by optical coherence tomography (OCT), causing significant angiographic stenosis and eligible for revascularization through percutaneous coronary intervention (PCI).

Patients will be randomized in a 1:1 ratio to undergo lesion preparation with either orbital atherectomy (OA) or intravascular lithotripsy (IVL).

The ORBIT-SHOCK pilot study is a multicenter, prospective, randomized clinical trial initiated by investigators. It will include patients diagnosed with atherosclerotic coronary artery disease presenting calcified nodules (CN), identified by optical coherence tomography (OCT), causing significant angiographic stenosis and eligible for revascularization through percutaneous coronary intervention (PCI). Patients will be randomized in a 1:1 ratio to undergo lesion preparation with either orbital atherectomy (OA) or intravascular lithotripsy (IVL).

The aim of this pilot trial is to compare PCI outcomes and the incidence of adverse events between both techniques.

Read the detailed description

Coronary calcification in the form of calcified nodules (CN) is systematically associated with worse outcomes due to the difficulty in adequately dilation of the lesion and the inability to properly fracture the calcium nodule before stent implantation.

The ORBIT-SHOCK pilot study is a multicenter, prospective, randomized clinical trial initiated by investigators. It will include patients diagnosed with atherosclerotic coronary artery disease presenting CNs, identified by optical coherence tomography (OCT), causing significant angiographic stenosis and eligible for revascularization through percutaneous coronary intervention (PCI).

Patients will be randomized in a 1:1 ratio to undergo lesion preparation with either orbital atherectomy (OA) or intravascular lithotripsy (IVL).

Primary endpoint: Compare both techniques in terms of achieving adequate stent expansion, measured by OCT.

Secondary endpoints: Evaluate procedural and strategy success rates, assess their impact on calcium nodule modification, and monitor the incidence of adverse clinical events at 12 months.

Patients will be monitored for 12 months after the procedure to assess the incidence of adverse events during follow-up.

03

Conditions studied

  • Coronary Arterial Disease (CAD)
  • Coronary Calcification
  • Coronary Calcified Nodules
  • Orbital Atherectomy
  • Intravascular Lithotripsy
  • Optical Coherence Tomography (OCT)
  • Percutaneous Coronary Intervention (PCI)
  • Chronic Coronary Syndrome
  • Acute Coronary Syndrome (ACS)

Keywords

  • Coronary arterial disease
  • Coronary calcification
  • Coronary calcified nodules
  • Orbital atherectomy
  • Intravascular lithotripsy
  • Optical Coherence Tomography (OCT)
  • Percutaneous Coronary Intervention (PCI)
  • Chronic Coronary Syndrome
  • Acute Coronary Syndrome (ACS)
  • ORBIT-SHOCK
  • ORBIT SHOCK
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients aged ≥ 18 years.
  2. Atherosclerotic coronary artery disease with calcified nodules identified by OCT in a native vessel, eligible for percutaneous coronary revascularization.
  3. Clinical presentation of chronic coronary syndrome or acute coronary syndrome without ST elevation*.
  4. Distal vessel reference diameters ≥ 2.5 mm and ≤ 4.0 mm. * Non-culprit lesions eligible for revascularization in a staged procedure following a ST-elevation myocardial infarction (STEMI) are considered for inclusion.

Exclusion criteria

Exclusion Criteria:

  1. Culprit lesions in acute coronary syndrome with ST elevation.
  2. Left main disease.
  3. In-stent restenosis lesions.
  4. Critical stenoses where it is not possible to advance the OCT catheter across the lesion after predilation with a balloon of up to 2 mm in diameter.
  5. Lesion involving a bifurcation with a secondary branch diameter ≥2 mm.
  6. Cardiogenic shock.
  7. Patients requiring cardiac surgery or percutaneous valve intervention within three months before or after angioplasty.
  8. Pregnancy.
  9. of less than one year.
  10. for the use of appropriate antiplatelet therapy post-revascularization.
  11. Coronary artery disease with an indication for surgical revascularization.
  12. Advanced chronic kidney disease or anatomical characteristics that contraindicate the use of optical coherence tomography.
  13. Inability to obtain .
  14. Allergy to eggs or soy, contraindicating the use of OA.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Active comparator
    Orbital atherectomy

    The Diamondback-360 (OAS) (Abbott) device is used to perform this technique, consisting of a bidirectional, diamond-coated orbital crown that utilizes a combination of centrifugal force (creating elliptical orbits) and surface abrasion to modify the calcified plaque and increase distensibility. Additionally, the pulsatile impact of the crown at high speed can create microfractures in deep calcium. As a result, a single 1.25 mm crown can treat vessels ranging from 2.5 to 4 mm in diameter.

    Device: Orbital atherectomy · Device: Optical Coherence Tomography (OCT) · Device: Percutaneous coronary intervention with stent implantation

  • Active comparator
    Intravascular lithotripsy

    The Shockwave Medical Intravascular Lithotripsy System (Shockwave Medical) is a balloon that emits pulsatile sonic waves capable of fracturing intracoronary calcium. This therapy is administered by advancing a catheter and inflating the balloon at low pressure to deliver sonic pulses.

    Device: Intravascular lithotripsy · Device: Optical Coherence Tomography (OCT) · Device: Percutaneous coronary intervention with stent implantation

Interventions

  • DeviceOrbital atherectomy

    The Diamondback-360 (OAS) (Abbott) device is used to perform this technique, consisting of a bidirectional, diamond-coated orbital crown that utilizes a combination of centrifugal force (creating elliptical orbits) and surface abrasion to modify the calcified plaque and increase distensibility. Additionally, the pulsatile impact of the crown at high speed can create microfractures in deep calcium. As a result, a single 1.25 mm crown can treat vessels ranging from 2.5 to 4 mm in diameter.

  • DeviceIntravascular lithotripsy

    The Shockwave Medical Intravascular Lithotripsy System (Shockwave Medical) is a balloon that emits pulsatile sonic waves capable of fracturing intracoronary calcium. This therapy is administered by advancing a catheter and inflating the balloon at low pressure to deliver sonic pulses.

    Also known as: Shockwave

  • DeviceOptical Coherence Tomography (OCT)

    Optical Coherence Tomography (OCT) is an intravascular imaging modality that uses near-infrared light to provide high-definition, cross-sectional and three-dimensional images of the vessel microstructure. These images provide additional information on the degree and characteristics of coronary artery disease compared to angiography which doesn't delineate the composition of the coronary artery. With automated, highly accurate measurements, OCT can guide stent selection, placement, and deployment.

  • DevicePercutaneous coronary intervention with stent implantation

    All patients will undergo percutaneous coronary intervention with drug-eluting stent implantation after plaque modification using the technique assigned by randomization.

06

What researchers measure

Primary outcomes

  1. Stent expansion

    Percentage of stent expansion at the CN site: measured with OCT, defined as the ratio between the minimum stent area at the CN site and the average of the distal and proximal reference areas.

    Time frame: At the end of percutaneous coronary intervention

Secondary outcomes

  1. Procedural success

    Achieving a stent expansion of ≥ 80% with TIMI III flow, in the absence of stent loss, coronary perforation, or intraprocedural death.

    Time frame: At the end of percutaneous coronary intervention

  2. Strategy success

    Defined as procedural success without the need for crossover to an alternative treatment.

    Time frame: At the end of percutaneous coronary intervention

  3. Minimum stent area

    Minimum stent area (MSA)

    Time frame: At the end of percutaneous coronary intervention

  4. Minimum stent area at the CN site.

    Minimum stent area at the CN site.

    Time frame: At the end of percutaneous coronary intervention

  5. Significant stent malapposition at the CN site

    Measured using OCT, defined as a stent strut detachment ≥ 0.4 mm from the underlying vessel wall, with a longitudinal extension ≥ 1 mm.

    Time frame: At the end of percutaneous coronary intervention

  6. Degree of calcium nodule debulking

    Reduction in calcium nodule size (mm²), measured after plaque modification and prior to stent implantation.

    Time frame: At the end of percutaneous coronary intervention

  7. Evidence of fracture at the CN site

    Evidence of new disruption or discontinuity observed on OCT after plaque modification and prior to stent implantation.

    Time frame: At the end of percutaneous coronary intervention

  8. Degree of stent ellipticity at the CN site

    Measured using OCT at the end of the procedure, calculated as the ratio of the maximum luminal diameter to the minimum luminal diameter of the stent at the CN site.

    Time frame: At the end of percutaneous coronary intervention

  9. Residual luminal protrusion of the calcium nodule following stent implantation

    Residual luminal protrusion of the calcium nodule following stent implantation, measured by OCT in mm2.

    Time frame: At the end of percutaneous coronary intervention

  10. Target lesion failure (TLF) at 12 months

    Composite of clinically driven target lesion revascularization, myocardial infarction or cardiac death related to the target lesion.

    Time frame: At 12 months

  11. Target lesion revascularization (TLR) at 12 months

    Repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion.

    Time frame: At 12 months

  12. Major Adverse Cardiovascular Events (MACE) at 12 months

    Defined as a composite of cardiovascular death, non-fatal target lesion myocardial infarction, unplanned target lesion revascularization or stent thrombosis.

    Time frame: At 12 months

07

Study locations

6 of 6 sites recruiting
  • Hospital Universitario General de Alicante
    Alicante, Alicante 03010, Spain
    Recruiting
    • José Valencia-Martín, MD, PhD. · Contactjvalenciam@hotmail.com · 0034 699 43 83 76
    • José Valencia-Martín, MD, PhD. · Principal investigator
  • Hospital Universitario Lucus Augusti
    Lugo, Lugo 27003, Spain
    Recruiting
    • Jeremías Bayón Lorenzo, MD, PhD. · Contactjerebayon@gmail.com · 0034 657 51 45 08
    • Jeremías Bayón Lorenzo, MD, PhD. · Principal investigator
  • Hospital Universitario Ramón y Cajal
    Madrid, Madrid 28034, Spain
    Recruiting
    • Ángel Sánchez-Recalde, MD, PhD. · Contactasrecalde@hotmail.com · 0034 676 59 95 32
    • Luis Manuel Domínguez-Rodríguez, MD. · Contactluis-s-ma@hotmail.com · 0034 639 82 56 65
    • Ángel Sánchez-Recalde, MD, PhD. · Principal investigator
    • Luis Manuel Domínguez-Rodríguez, MD. · Principal investigator
  • Hospital Universitario de Salamanca
    Salamanca, Salamanca 37007, Spain
    Recruiting
    • Javier Martín-Moreiras, MD, PhD. · Contactjmmoreiras@gmail.com · 0034 629 25 31 16
    • Javier Martín-Moreiras, MD, PhD. · Principal investigator
  • Hospital Clínico Universitario de Valladolid
    Valladolid, Valladolid 47003, Spain
    Recruiting
    • Jesús Ignacio Amat-Santos, MD, PhD. · Contactijamat@gmail.com · 0034 657 92 30 40
    • Jesús Ignacio Amat-Santos, MD, PhD. · Principal investigator
  • Hospital Universitario Reina Sofía de Córdoba
    Córdoba, Spain
    Recruiting
08

References and documents

Publications

  • Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011 Jun 14;123(23):2736-47. doi: 10.1161/CIRCULATIONAHA.110.009449. No abstract available. PubMed 21670242 ↗
  • Lansky AJ, Messe SR, Brickman AM, Dwyer M, van der Worp HB, Lazar RM, Pietras CG, Abrams KJ, McFadden E, Petersen NH, Browndyke J, Prendergast B, Ng VG, Cutlip DE, Kapadia S, Krucoff MW, Linke A, Moy CS, Schofer J, van Es GA, Virmani R, Popma J, Parides MK, Kodali S, Bilello M, Zivadinov R, Akar J, Furie KL, Gress D, Voros S, Moses J, Greer D, Forrest JK, Holmes D, Kappetein AP, Mack M, Baumbach A. Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials: An Academic Research Consortium Initiative. J Am Coll Cardiol. 2017 Feb 14;69(6):679-691. doi: 10.1016/j.jacc.2016.11.045. PubMed 28183511 ↗
  • Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD; ESC Scientific Document Group. Fourth universal definition of myocardial infarction (2018). Eur Heart J. 2019 Jan 14;40(3):237-269. doi: 10.1093/eurheartj/ehy462. No abstract available. PubMed 30165617 ↗
  • Garcia-Garcia HM, McFadden EP, Farb A, Mehran R, Stone GW, Spertus J, Onuma Y, Morel MA, van Es GA, Zuckerman B, Fearon WF, Taggart D, Kappetein AP, Krucoff MW, Vranckx P, Windecker S, Cutlip D, Serruys PW; Academic Research Consortium. Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document. Eur Heart J. 2018 Jun 14;39(23):2192-2207. doi: 10.1093/eurheartj/ehy223. PubMed 29897428 ↗
  • Maehara A, Ben-Yehuda O, Ali Z, Wijns W, Bezerra HG, Shite J, Genereux P, Nichols M, Jenkins P, Witzenbichler B, Mintz GS, Stone GW. Comparison of Stent Expansion Guided by Optical Coherence Tomography Versus Intravascular Ultrasound: The ILUMIEN II Study (Observational Study of Optical Coherence Tomography [OCT] in Patients Undergoing Fractional Flow Reserve [FFR] and Percutaneous Coronary Intervention). JACC Cardiovasc Interv. 2015 Nov;8(13):1704-14. doi: 10.1016/j.jcin.2015.07.024. PubMed 26585621 ↗
  • Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, Banning AP, Budaj A, Buechel RR, Chiariello GA, Chieffo A, Christodorescu RM, Deaton C, Doenst T, Jones HW, Kunadian V, Mehilli J, Milojevic M, Piek JJ, Pugliese F, Rubboli A, Semb AG, Senior R, Ten Berg JM, Van Belle E, Van Craenenbroeck EM, Vidal-Perez R, Winther S; ESC Scientific Document Group. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024 Sep 29;45(36):3415-3537. doi: 10.1093/eurheartj/ehae177. No abstract available. PubMed 39210710 ↗
  • Holm NR, Andreasen LD, Neghabat O, Laanmets P, Kumsars I, Bennett J, Olsen NT, Odenstedt J, Hoffmann P, Dens J, Chowdhary S, O'Kane P, Bulow Rasmussen SH, Heigert M, Havndrup O, Van Kuijk JP, Biscaglia S, Mogensen LJH, Henareh L, Burzotta F, H Eek C, Mylotte D, Llinas MS, Koltowski L, Knaapen P, Calic S, Witt N, Santos-Pardo I, Watkins S, Lonborg J, Kristensen AT, Jensen LO, Calais F, Cockburn J, McNeice A, Kajander OA, Heestermans T, Kische S, Eftekhari A, Spratt JC, Christiansen EH; OCTOBER Trial Group. OCT or Angiography Guidance for PCI in Complex Bifurcation Lesions. N Engl J Med. 2023 Oct 19;389(16):1477-1487. doi: 10.1056/NEJMoa2307770. Epub 2023 Aug 27. PubMed 37634149 ↗
  • Ali ZA, Landmesser U, Maehara A, Matsumura M, Shlofmitz RA, Guagliumi G, Price MJ, Hill JM, Akasaka T, Prati F, Bezerra HG, Wijns W, Leistner D, Canova P, Alfonso F, Fabbiocchi F, Dogan O, McGreevy RJ, McNutt RW, Nie H, Buccola J, West NEJ, Stone GW; ILUMIEN IV Investigators. Optical Coherence Tomography-Guided versus Angiography-Guided PCI. N Engl J Med. 2023 Oct 19;389(16):1466-1476. doi: 10.1056/NEJMoa2305861. Epub 2023 Aug 27. PubMed 37634188 ↗
  • Lee JM, Choi KH, Song YB, Lee JY, Lee SJ, Lee SY, Kim SM, Yun KH, Cho JY, Kim CJ, Ahn HS, Nam CW, Yoon HJ, Park YH, Lee WS, Jeong JO, Song PS, Doh JH, Jo SH, Yoon CH, Kang MG, Koh JS, Lee KY, Lim YH, Cho YH, Cho JM, Jang WJ, Chun KJ, Hong D, Park TK, Yang JH, Choi SH, Gwon HC, Hahn JY; RENOVATE-COMPLEX-PCI Investigators. Intravascular Imaging-Guided or Angiography-Guided Complex PCI. N Engl J Med. 2023 May 4;388(18):1668-1679. doi: 10.1056/NEJMoa2216607. Epub 2023 Mar 5. PubMed 36876735 ↗
  • Shin D, Dakroub A, Singh M, Malik S, Sakai K, Maehara A, Shlofmitz E, Jeremias A, Shlofmitz RA, Ali ZA. Debulking Effect of Orbital Atherectomy for Calcified Nodule Assessed by Optical Coherence Tomography. Circ Cardiovasc Interv. 2024 Aug;17(8):e014145. doi: 10.1161/CIRCINTERVENTIONS.124.014145. Epub 2024 Jul 1. No abstract available. PubMed 38946577 ↗
  • Chiang CSM, Alan Chan KC, Lee M, Chan KT. Orbital-Tripsy: Novel Combination of Orbital-Atherectomy and Intravascular-Lithotripsy, in Calcified Coronaries After Failed Intravascular-Lithotripsy. JACC Case Rep. 2020 Dec 16;2(15):2437-2444. doi: 10.1016/j.jaccas.2020.10.027. eCollection 2020 Dec. PubMed 34317190 ↗
  • Rola P, Wlodarczak S, Barycki M, Furtan L, Jastrzebski A, Kedzierska M, Doroszko A, Lesiak M, Wlodarczak A. Safety and Efficacy of Orbital Atherectomy in the All-Comer Population: Mid-Term Results of the Lower Silesian Orbital Atherectomy Registry (LOAR). J Clin Med. 2023 Sep 8;12(18):5842. doi: 10.3390/jcm12185842. PubMed 37762782 ↗
  • Okamoto N, Ueda H, Bhatheja S, Vengrenyuk Y, Aquino M, Rabiei S, Barman N, Kapur V, Hasan C, Mehran R, Baber U, Kini AS, Sharma SK. Procedural and one-year outcomes of patients treated with orbital and rotational atherectomy with mechanistic insights from optical coherence tomography. EuroIntervention. 2019 Apr 20;14(17):1760-1767. doi: 10.4244/EIJ-D-17-01060. PubMed 29957595 ↗
  • Yamamoto MH, Maehara A, Karimi Galougahi K, Mintz GS, Parviz Y, Kim SS, Koyama K, Amemiya K, Kim SY, Ishida M, Losquadro M, Kirtane AJ, Haag E, Sosa FA, Stone GW, Moses JW, Ochiai M, Shlofmitz RA, Ali ZA. Mechanisms of Orbital Versus Rotational Atherectomy Plaque Modification in Severely Calcified Lesions Assessed by Optical Coherence Tomography. JACC Cardiovasc Interv. 2017 Dec 26;10(24):2584-2586. doi: 10.1016/j.jcin.2017.09.031. No abstract available. PubMed 29268891 ↗
  • Yamamoto MH, Maehara A, Kim SS, Koyama K, Kim SY, Ishida M, Fujino A, Haag ES, Alexandru D, Jeremias A, Sosa FA, Karimi Galougahi K, Kirtane AJ, Moses JW, Ali ZA, Mintz GS, Shlofmitz RA. Effect of orbital atherectomy in calcified coronary artery lesions as assessed by optical coherence tomography. Catheter Cardiovasc Interv. 2019 Jun 1;93(7):1211-1218. doi: 10.1002/ccd.27902. Epub 2018 Oct 17. PubMed 30328257 ↗
  • Okamoto N, Egami Y, Nohara H, Kawanami S, Sugae H, Kawamura A, Ukita K, Matsuhiro Y, Nakamura H, Yasumoto K, Tsuda M, Matsunaga-Lee Y, Yano M, Nishino M, Tanouchi J. Direct Comparison of Rotational vs Orbital Atherectomy for Calcified Lesions Guided by Optical Coherence Tomography. JACC Cardiovasc Interv. 2023 Sep 11;16(17):2125-2136. doi: 10.1016/j.jcin.2023.06.016. PubMed 37704299 ↗
  • Faria D, Vinhas H, Bispo J, Guedes J, Marto S, Palmeiro H, Franco P, Mimoso J. Initial experience with orbital atherectomy in a non-surgical center in Portugal. Rev Port Cardiol. 2024 Dec;43(12):659-665. doi: 10.1016/j.repc.2024.03.005. Epub 2024 Jul 8. English, Portuguese. PubMed 38986811 ↗
  • Florek K, Bartoszewska E, Biegala S, Klimek O, Malcharczyk B, Kubler P. Rotational Atherectomy, Orbital Atherectomy, and Intravascular Lithotripsy Comparison for Calcified Coronary Lesions. J Clin Med. 2023 Nov 23;12(23):7246. doi: 10.3390/jcm12237246. PubMed 38068298 ↗
  • Chambers JW, Feldman RL, Himmelstein SI, Bhatheja R, Villa AE, Strickman NE, Shlofmitz RA, Dulas DD, Arab D, Khanna PK, Lee AC, Ghali MG, Shah RR, Davis TP, Kim CY, Tai Z, Patel KC, Puma JA, Makam P, Bertolet BD, Nseir GY. Pivotal trial to evaluate the safety and efficacy of the orbital atherectomy system in treating de novo, severely calcified coronary lesions (ORBIT II). JACC Cardiovasc Interv. 2014 May;7(5):510-8. doi: 10.1016/j.jcin.2014.01.158. PubMed 24852804 ↗
  • Parikh K, Chandra P, Choksi N, Khanna P, Chambers J. Safety and feasibility of orbital atherectomy for the treatment of calcified coronary lesions: the ORBIT I trial. Catheter Cardiovasc Interv. 2013 Jun 1;81(7):1134-9. doi: 10.1002/ccd.24700. Epub 2013 Mar 5. PubMed 23460596 ↗
  • Ali ZA, Kereiakes D, Hill J, Saito S, Di Mario C, Honton B, Gonzalo N, Riley R, Maehara A, Matsumura M, Stone GW, Shlofmitz R. Safety and Effectiveness of Coronary Intravascular Lithotripsy for Treatment of Calcified Nodules. JACC Cardiovasc Interv. 2023 May 8;16(9):1122-1124. doi: 10.1016/j.jcin.2023.02.015. Epub 2023 Apr 5. No abstract available. PubMed 37029020 ↗
  • Akasaka T, Kubo T. OCT-derived coronary calcified nodules as a predictor of high-risk patients. EuroIntervention. 2020 Aug 28;16(5):361-363. doi: 10.4244/EIJV16I5A65. No abstract available. PubMed 32855116 ↗
  • Prati F, Gatto L, Fabbiocchi F, Vergallo R, Paoletti G, Ruscica G, Marco V, Romagnoli E, Boi A, Fineschi M, Calligaris G, Tamburino C, Crea F, Ozaki Y, Alfonso F, Arbustini E. Clinical outcomes of calcified nodules detected by optical coherence tomography: a sub-analysis of the CLIMA study. EuroIntervention. 2020 Aug 28;16(5):380-386. doi: 10.4244/EIJ-D-19-01120. PubMed 32310133 ↗
  • Ali ZA, Kereiakes DJ, Hill JM, Saito S, Di Mario C, Honton B, Gonzalo N, Riley RF, Maehara A, Matsumura M, Shin D, Stone GW, Shlofmitz RA. Impact of Calcium Eccentricity on the Safety and Effectiveness of Coronary Intravascular Lithotripsy: Pooled Analysis From the Disrupt CAD Studies. Circ Cardiovasc Interv. 2023 Oct;16(10):e012898. doi: 10.1161/CIRCINTERVENTIONS.123.012898. Epub 2023 Oct 17. PubMed 37847770 ↗
  • McInerney A, Travieso A, Jeronimo Baza A, Alfonso F, Del Val D, Cerrato E, Garcia de Lara J, Pinar E, Perez de Prado A, Jimenez Quevedo P, Tirado-Conte G, Nombela-Franco L, Brugaletta S, Cepas-Guillen P, Sabate M, Cubero Gallego H, Vaquerizo B, Jurado A, Varbella F, Jimenez M, Garcia Escobar A, de la Torre JM, Amat Santos I, Jimenez Diaz VA, Escaned J, Gonzalo N. Impact of coronary calcium morphology on intravascular lithotripsy. EuroIntervention. 2024 May 20;20(10):e656-e668. doi: 10.4244/EIJ-D-23-00605. PubMed 38776142 ↗
  • Brott BC. The Calcified Nodule Paradox. JACC Cardiovasc Interv. 2023 May 8;16(9):1036-1038. doi: 10.1016/j.jcin.2023.04.001. No abstract available. PubMed 37164600 ↗
  • Sato T, Matsumura M, Yamamoto K, Shlofmitz E, Moses JW, Khalique OK, Thomas SV, Tsoulios A, Cohen DJ, Mintz GS, Shlofmitz RA, Jeremias A, Ali ZA, Maehara A. Impact of Eruptive vs Noneruptive Calcified Nodule Morphology on Acute and Long-Term Outcomes After Stenting. JACC Cardiovasc Interv. 2023 May 8;16(9):1024-1035. doi: 10.1016/j.jcin.2023.03.009. PubMed 37164599 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Dec 2026, 18 months after the start.

Of 213 non-industry interventional studies with no phase under Acute Coronary Syndrome, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 46. This study's planned 18 months is below that.

Counting every sponsor, half of 228 studies reached it within 34 months; a quarter within 17 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2024
First posted
Dec 17, 2024
StartActual
Jun 12, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2027
Last update
Apr 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06736665
Lead sponsor
Spanish Society of Cardiology
Collaborators
Abbott
Responsible party
Luis Manuel Domínguez Rodríguez (Interventional Cardiologist and Clinical Researcher, Spanish Society of Cardiology) — Principal investigator
First posted
Dec 17, 2024
Start date
Jun 12, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Apr 30, 2026

Study contacts

Ángel Sánchez-Recalde, MD, PhD.
Contact
asrecalde@hotmail.com
0034 676 59 95 32
Luis Manuel Domínguez-Rodríguez, MD.
Contact
luis-s-ma@hotmail.com
0034 639 82 56 65

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion